Morin enhances the renoprotective effects of Empagliflozin in diabetic kidney disease via targeting ATF6-DAPK1 signaling

2026/05/28 by Yi Lei, CHENLIN GAO, Chenlin Gao +9 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Chronic Kidney Disease and Diabetes #Diabetes Treatment and Management #Metabolism, Diabetes, and Cancer

paper · doi:10.1016/s1875-5364(26)61187-9

openalex publication_date 2026/05/28 · crossref created 2026/05/28 · crossref deposited 2026/05/28 · crossref indexed 2026/05/28 · openalex created_date 2026/05/29 · crossref issued 2026/06/01 · crossref published 2026/06/01 · crossref published-print 2026/06/01 · openalex updated_date 2026/07/23

Citations

• Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
• Endoplasmic reticulum stress contributes to pyroptosis through NF-κB/NLRP3 pathway in diabetic nephropathy

Discussions

• Synergistic renoprotection in DKD! 🧪 CJNM research shows Morin enhances Empagliflozin’s effects by targeting ATF6-DAPK1, reducing oxidative stress & apoptosis. 🩺🔬 🔗 doi.org/10.1016/S187... #Dia [bsky, 1 points, 0 comments]